The European Medicines Agency has validated the marketing authorization application for abicipar, Molecular Partners announced.
If approved, abicipar, a novel DARPin therapy for the treatment of wet age-related macular degeneration, would be the first anti-VEGF therapy to sustain vision gains on a fixed 12-week dosing interval, a press release said.
The validation allows a formal review process to begin.
Allergan, Molecular Partners’ strategic partner, submitted the application.
Uncategorized